DILIsym® Services may be utilized by companies involved in the research and development of drugs or chemicals, including services such as conducting simulations of drug-liver interactions, and designing computer software for companies to be used in modeling liver responses to a drug or chemical.
DILIsym Services, Inc. has the overarching goal of applying the DILIsym software to improve the safety profiles of therapeutics reaching the market. To achieve this goal, three significant objectives have been developed:
- Inform and impact the candidate selection process for therapeutic development teams in the preclinical development space as they prioritize the progression of compounds not yet taken into man;
- Provide information regarding the risk aspect of the risk versus benefit question often debated as large investments are considered to progress compounds from early stage clinical development to later stage, larger trials;
- Identify and/or substantiate precision medicine approaches from a safety perspective that may allow therapeutics to reach a majority of the target patient population without harming a few.
DILIsym Services also has the goal of aiding the successful development of medicines to treat nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). This goal is accomplished via the use of our newest product, NAFLDsym, to partner with pharmaceutical companies in this endeavor.
DSSI has multiple software platforms to support biotechnology and pharmaceutical companies in the development of safe and effective treatments. These software platforms support DILI-sim Initiative and DSSI goals of improving patient safety, reducing the need for animal testing, and reducing the costs and time necessary to develop new drugs. Click on the software submodules titles on the right hand to learn more.
The DILI-sim Initiative is a consortium of life science companies led by DILIsym Services, Inc. and charged with developing DILIsym software, a predictive, mathematical model of drug-induced liver injury. The goals of the Initiative are to improve patient safety, reduce the need for animal testing, and reduce the costs and time necessary to develop new drugs. DILI-sim is currently welcoming new members. Perhaps most importantly, DILI-sim members have a prevailing voice in the development plan of the DILIsym software, ensuring that the model will be of maximum utility as it is developed within their respective organizations. Members also get the chance to hear and learn from one another at regular virtual and face to face meetings, where scientific discussions centered around DILI occur.The DILI-sim Initiative